· COVID-19 raises awareness of the benefits of suPAR testing · Financial target reduced but pilot customers increased · We reiterate our fair value interval of DKK 68.50 – 100.50 per share We have reviewed our analysis of ViroGates following the release of its Annual Report for 2019 last week. We have seen both good and bad news since our Initial Research report in January. At this stage, it is impossible to say whether the positives or negatives should be given more weight, so we maintain our valuation range and general view of the investment case while stressing that uncertainty has increased markedly. The full report is available here (https://www.vhcorp.se/uploads/1389_Virogates_update_200330.pdf?pdf=Virogates_update_200330.pdf). The research report is prepared as part of Market Focus, Västra Hamnen Corporate Finance's commissioned research offering. This is a press release from Västra Hamnen Corporate Finance AB.  Web: vhcorp.se Twitter: @vhcorp_se (https://twitter.com/vhcorp_se)